M. ASHRAF CHAUDHARY, MSc PhD

Clarksburg MD ***** 215-***-**** ad05sg@r.postjobfree.com linkedin.com/in/AshrafChaudhary Exceptional proven experience as a Global/US HEOR lead including HEOR strategic planning, pre- and post-launch, RW treatment patterns and COA. Impactful professional adept in HEOR strategic input into clinical trial designs; predictive reimbursement analysis - POC to Phase III. Committed to collaborative teamwork, empathetic listening and life-long learning. Core competencies include: Economic Modeling (Cost-effectiveness, Budget Impact and Predictive CE Modeling) Systematic Literature Reviews Indirect Treatment Comparisons Supplementary Analysis of Clinical Trials Real World Evidence US and Global HTA & Reimbursement HTA Consultations

THERAPY AREAS

Immune-oncology therapies in non-small cell lung cancer (NSCLC); mesothelioma; breast cancer; squamous cell carcinoma of head and neck (SCCHN); glioblastoma (GBM); melanoma; HIV/AIDS; inflammation and immunology therapies in rheumatoid arthritis (RA), ankylosing spondylitis (AS); psoriasis, Crohn’s disease, ulcerative colitis; lupus (SLE), lupus nephritis (LN)

EXPERIENCE

Bristol Myers Squibb (BMS), Princeton NJ 2018 - 2023 Director, Worldwide Health Economics and Outcomes Research (HEOR) Oncology 2018 - 2023 Champion best in class HEOR payer analytics including cost-effectiveness models, Real world Evidence [Flatiron, US Oncology (McKesson), IQVIA], SLR and NMA, cross-over adjustment and predictive reimbursement analysis to support governance Go/No-Go decisions in close collaboration with product leads in market access, medical affairs, and pricing.

• Demonstrated the value of HEOR initiatives to secure funding.

• Led the BMS external strategy to evolve the assessment of overall survival in immuno-oncology; horizon scanning key developments in economic modeling methodology and international/ national standards.

• Early modeling for strategic input to development design and pricing strategy; and input to core global models; local country model adaptations and for Health Technology Assessment (HTA) and budget impact models.

• Tumor types: non-small cell lung cancer (1L, 2L+, non-metastatic); glioblastoma; SCCHN; breast Cancer Bristol Myers Squibb (BMS), Princeton NJ

Director/Consultant HEOR US HEOR Oncology BMS 2017 – 2018 Leading matrix team (product leads in market access and medical affairs) to develop and align HEOR strategy for relatlimab (anti-LAG-3) in melanoma to demonstrate the value to health care customers.

• Demonstrated the value of HEOR initiatives to secure funding.

• Developed product value propositions by incorporating RWE/HEOR evidence to achieve market access Selecting external organizations and KOLs for collaboration Leading RWE projects [Flatiron, US Oncology

(McKesson), IQVIA] from concept through execution (Reporting evidence at scientific meetings; peer reviewed publications; develop proactive and reactive BMS communication tools (FDAMA 114 and promotional resources) and support regulatory filing with RWE.

• Created preliminary economic model to explore value-based pricing for relatlimab in melanoma for US Payer Marketing and Access.

AstraZeneca 2014 – 2017

Director, Health Economics and Payer Analytics

• Took charge of crafting and executing comprehensive global HEOR (Health Economics and Outcomes Research) strategies, with the overarching goal of securing worldwide patient access by showcasing the M. Ashraf Chaudhary, MSc, PhD

September 23

2

inherent value of company's immunology and oncology assets in close collaboration with product leads in market access, medical affairs, and pricing.

• Therapeutic Areas: Inflammation and Immunology (Crohn’s Disease and Ulcerative Colitis; Lupus

(Systemic lupus erythematosus (SLE), Lupus nephritis (LN)) and Immuno-oncology (NSCLC and SCCHN). Merck and Co. 2007 – 2014

Associate Director/Director/Senior Principal Scientist, Health Economic Statistics Led the generation of evidence to support scientific and commercial value of products to optimize access and reimbursement in close collaboration with product leads in market access, medical affairs, and pricing. Hands-on development of economic models, analysis of clinical trials and real-world databases (SAS & R), direct interactions with HTA bodies, NICE, CADTH

• Therapeutic Areas: HIV/AIDS; Inflammation and immunology (UC; CD; RA, Ankylosing Spondylitis; Psoriasis; PsA).

Johns Hopkins Bloomberg School of Public Health 2004 – 2007 Associate Scientist/Principal Biostatistician

• Principal biostatistician on large international public health studies on HIV/AIDS and TB; Hands-on statistical analysis using SAS and R for presentations at NIAID DSMBs and for peer-reviewed publications. EDUCATION

PhD, Biostatistics/Epidemiology, University. North Carolina at Chapel Hill MSc, Social Statistics/Demography, University Southampton, UK PUBLICATIONS

BOOK: Analysis of Correlated Data with SAS and R, Chapman, and Hall/CRC; 3rd edition, 2007, Shoukri MM and Chaudhary MA

26 (of 60+) Peer Reviewed Articles

1. Anthony J. Hatswell, Chaudhary MA, Monnickendam G, Moreno-Koehler A, Frampton K, Shaw JW, Penrod JR, Lawrance R, Modelling health state utilities as a transformation of time to death in patients with NSCLC, PharmacoEconomics

(2023). https://doi.org/10.1007/s40273-023-01314-2 2. Chaudhary MA, Edmondson-Jones M, Baio G, Mackay E, Penrod JR, Harris G, Rafiq S, Johannesen K, Siddiqui MK, Vanderpuye-Orgle J, Briggs A, Use of advanced flexible modelling approaches for survival extrapolation from early follow-up data in two nivolumab trials in advanced NSCLC with extended follow-up, Medical Decision Making 43.1

(2023): 91-109.

3. Polyzoi M, Sandhu H, Maervoet J, Yuan Y, Chaudhary MA, Varol N, Lee A, Dale P, Jones C, Lubinga SJ and Penrod JR, Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. Journal of Medical Economics 25.1 (2022): 660-668. 4. Berling M, Chaudhary MA, Yuan Y, Varol N, Dale P, Testa E, Klint J, Lee A, Lubinga SJ and Penrod JR, Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. Journal of Medical Economics 25.1 (2022): 703-711. 5. Chaudhary MA, Lubinga SJ, Smare C, Hertel N, Penrod JR, Cost-Effectiveness of Nivolumab in Squamous and Non- squamous NSCLC Non-Small Cell Lung Cancer in United States, American Journal of Managed Care 27.8 (2021). 6. Chaudhary MA, Holmberg C, Smare C, Lakhdari K, Smare C, Penrod JR, Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data, Journal of Medical Economics 24.1 (2021): 607-619.

7. Borse RH, Brown C, Muszbek N, Chaudhary MA, Kachroo S. Cost-effectiveness of golimumab in ankylosing spondylitis from the UK payer perspective. Rheumatology and Therapy (2017) 8. Chaudhary MA, Fan, Tao. Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. Biologics in Therapy, Volume 3, Issue 1, 2013, 45-60 9. Chaudhary MA, Elbasha EH, Kumar RN, Nathanson EC. Cost-effectiveness of raltegravir in HIV/AIDS: a review. Expert Review of Pharmacoeconomics & Outcomes Research 2011, 11(6), 627–639 M. Ashraf Chaudhary, MSc, PhD

September 23

3

10. Elbasha EH, Szucs T, Chaudhary MA, RN Kumar RN,3 Roediger A, Cook HR and M Opravil. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clinical Trials 2009, 10(4): 233-253.

11. Chaudhary MA, Moreno, S, Kumar, RN, Nocea, G, Elbasha EH. Cost-effectiveness analysis of raltegravir in treatment- experienced HIV-1 infected patients in Spain. AIDS Research and Human Retroviruses 2009, 25(7): 679-89. 12. Omer, SB. Bedri A, Gudetta B, Isehak A, Kumbi S, Mengistu Y, Bhore AV, Bhosale R, Gupte N, Sastry J, Suryavanshi N, Tripathy S, Varadhrajan V, Mmiro F, Mubiru M, Musoke P, Nakabiito C, Onyango C, Taylor A, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwerski S. Twelve-month follow-up of six week extended dose nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS 25.6 2011: 767-776. 13. Chaisson, RE, Chaudhary MA & Conde MB. Moxifloxacin versus ethambutol in initial tuberculosis treatment–Authors' reply. Lancet 2009 373(9682): 2198-2199.

14. Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE, Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373(9670): 1183-9

15. Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, Bhore AV, Bhosale R, Varadhrajan V, Gupte N, Sastry J, Suryavanshi N, Tripathy S, Mmiro F, Mubiru M, Onyango C, Taylor A, Musoke P, Nakabiito C, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwerski S. Extended Dose Nevirapine to Six Weeks of Age for Infants in Ethiopia, India and Uganda:A Randomized Study for Prevention of HIV Transmission to Breastfed Infants, Lancet 2008; 372: 300-13

16. Diana S. Pope, Andrea N. DeLuca, Paula Kali, Harry Hausler, Carol Sheard, Ebrahim Hoosain, Chaudhary MA, David D. Celentano, and Richard E. Chaisson, A Cluster-Randomized Trial of Provider-Initiated (Opt-Out) HIV Counseling and Testing of Tuberculosis Patients in South Africa, Journal of Acquired Immune Deficiency Syndromes 2008;48:190–195 17. A Randomized Trial of Male Circumcision for HIV Prevention in Men; Rakai, Uganda; Ronald H. Gray, Godfrey Kigozi, David Serwadda, Frederick Makumbi, Stephen Watya, Fred Nalugoda, Noah Kiwanuka, Lawrence H. Moulton, Chaudhary MA, Michael Z Chen, Nelson K. Sewankambo, Fred Wabwire-Mangen, Melanie C. Bacon, Carolyn Williams, Pius Opendi, Steven J Reynolds, Oliver Laeyendecker, Thomas C Quinn, Maria J. Wawer, Lancet 2007; 369: 657–66 18. Chaudhary, MA and Moulton, LH, A SAS Macro for Constrained Randomization of Group Randomized Trials, Computer Methods and Programs in Biomedicine, September 2006, Volume 83, Issue 3, 205-210. 19. Asim F. Belgaumi, Lobna Shalaby, Amani Al-Kofide, Chaudhary MA, Christopher Alviedo, Rajeh Sabbah: Treatment of a Clinically Determined Lower-Risk Subset of Stage III Non-Lymphoblastic Non-Hodgkin Lymphoma with Less Intensive Therapy does not Impact Negatively on Outcome, Journal of Pediatric Blood and Cancer 2006; 46(3): 367-71. 20. Shoukri MM, Chaudhary MA, and Al-Halees, A.: Estimating P(Y < X) when X and Y are Paired Exponential Variables. Journal of Statistical Computation and Simulation, 2005; Vol. 75, No. 1, 25-38. 21. Shoukri, M.M., Chaudhary MA and Asyali M.H.: Confidence Intervals for Limiting Availability Assuming Correlated Rayleigh Random Variables. Journal of Statistical Research, Vol. 37, No. 2, 183-191, 2003. 22. Gutierrez, M.I., Siraj, A.K., Bhargava M., Ozbek, U., Banawali S., Chaudhary MA, El Solh H., Bhatia K.: Concurrent Methylation of Multiple Genes in Childhood ALL: Correlation with Phenotype and Molecular Subgroup. Leukemia, Vol. 17, 1845-1850, 2003.

23. Shoukri M.M., Chaudhary MA, Mohamed G.H.: Evaluating Normal Approximation Confidence Intervals for Measures of 2x2 Associations with Applications to Twin Data. Biometrical Journal, Vol. 44, 1-14, 2002. 24. Chaudhary MA, and Hannan, M.A.: A SAS Macro for the Analysis of Cell Survival Curves, Computer Methods and Programs in Biomedicine. Vol. 67, 201-207, 2002.

25. Chaudhary MA and Sen, Pranab K.: Reconciliation of Asymptotics for UPS Sampling Without Replacement, Journal of Statistical Planning and Inference. Vol. 102, Issue 1, 71-81, 2002. 26. Chaudhary MA, and Stearns, Sally C.: Estimating Confidence Intervals for Cost-Effectiveness Ratios: An Example from a Randomized Trial. Statistics in Medicine, Vol. 15, 1447-1458, 1996 44 (of 100+) Abstracts / Posters / Presentations

1. Mack Harris, Lien Vo, Ariel Sun, Benjamin White, Sandra Milev, Chaudhary MA, Ray Saurabh, Stefano Lucherini, Cost-Effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC in the US, accepted for AMCP Nexus 2023, Orlando, FL, Oct. 16- Oct. 19, 2023 2. Libanore A, Lee A, Baginska B, Chaudhary MA, Maervoet J, Ray S, Yuan Y, Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients with Stage IV or Recurrent Non-Small M. Ashraf Chaudhary, MSc, PhD

September 23

4

Cell Lung Cancer in the United States, submitted ISPOR Annual European Congress, November 12-15, 2023, Copenhagen, Denmark

3. Sharpe D, Yates G, García-Fernández L, Yuan Y, Lee A, Chaudhary MA, Extending Bayesian Evidence Synthesis to Include Historical Trial Data for Improved Survival Extrapolations from Early Data Cuts in Metastatic Non-Small Cell Lung Cancer (mNSCLC), submitted ISPOR Annual European Congress, November 12-15, 2023, Copenhagen, Denmark

4. Sharpe D, Yates G, García-Fernández L, Yuan Y, Lee A, Chaudhary MA, Formulating Bayesian Poly-Hazard Models for Informed and Clinically Interpretable Lifetime Survival Extrapolations in Advanced Non-Small Cell Lung Cancer (aNSCLC), submitted ISPOR Annual European Congress, November 12-15, 2023, Copenhagen, Denmark 5. Young R, Yuan Y, Chaudhary MA, Lee A, Gordon J, McEwan P, When Should I Mix? Improving Understanding of the Predictive Behavior of Mixture-Cure Survival Models Informed By Immature Data, submitted ISPOR Annual European Congress, November 12-15, 2023, Copenhagen, Denmark 6. Goring S, Rogula B, Lucherini S, Vo L, Lozano-Ortega G, Besada M, Chaudhary MA, Varol N, Lam P, Girard N, Spicer J, Indirect Treatment Comparisons of Time-to-Event Outcomes with Mis-Matched ‘Time Zero’: Methodology and Application in Resectable Non-Small Cell Lung Cancer, 2023-05, ISPOR 2023, Boston, MA, USA, Value in Health, Volume 26, Issue 6, S2 (June 2023)

7. Sharpe D, Yates G, García-Fernández L, Yuan Y, Lee A, Chaudhary MA, Application of Bayesian Multi-Parameter Evidence Synthesis to Achieve Clinical Plausibility of Lifetime Survival Extrapolations in First-Line Advanced Non- Small Cell Lung Cancer (aNSCLC), 2023-05, ISPOR 2023, Boston, MA, USA, Value in Health, Volume 26, Issue 6, S2 (June 2023)

8. Anthony J. Hatswell, Chaudhary MA, Alejandro Moreno-Koehler, James W. Shaw, John R. Penrod, Rachael Lawrance, Modelling time-to-death utilities as a continuous function, using a rich dataset of patients with non-small cell lung cancer, ISPOR Annual European Congress, # PCR154, November 6-9, 2022, Vienna, Austria 9. Griffiths A, Young R, Yuan Y, Chaudhary MA, Lee A, Gordon J, McEwan P, Health economic evaluation incorporating mixture cure survival analysis of nivolumab plus ipilimumab for previously untreated metastatic NSCLC, ISPOR Annual European Congress, # EE513, November 6-9, 2022, Vienna, Austria 10. Young R, Pritchard C, Yuan Y, Chaudhary MA, Lee A, Gordon J, McEwan P, Mixture-cure modelling of overall survival of patients with metastatic non-small cell lung cancer receiving nivolumab + ipilimumab in CheckMate 227 – updated with 5 years of follow-up, ISPOR Annual European Congress, # MSR16, November 6-9, 2022, Vienna, Austria

11. Reck M, De T, Paz-Ares L, Yuan Y, Chaudhary MA, Lee A, Varol N, Penrod JR, Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer, European Society of Medical Oncology ESMO Congress, 1026P, September 9-13, Paris, France [Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064]

12. Young R, Pritchard C, Yong Y, Chaudhary MA, Lee A, Gordon J, McEwan P, Mixture-Cure Modelling of the Overall Survival Outcomes of Patients with Advanced Non-small Cell Lung Cancer (aNSCLC) Receiving Nivolumab

+ Ipilimumab in CheckMate 227, ISPOR 27th Annual International Meeting, MSR68, May 15-18, 2022 [Published Value in Health 25.7 (2022): S531]

13. Berling M, Chaudhary MA, Yuan Y, Varol N, Dale P, Testa E, Klint J, Lee A, Lubinga SJ, Penrod JR, Cost- effectiveness analysis of nivolumab plus ipilimumab in the first-line treatment of metastatic non-small cell lung cancer in the United States, Virtual IASLC 2020 North America Conference on Lung Cancer, October 16-17, 2020 14. Mackay E, Chaudhary MA, Vanderpuye-Orgle J, Edmondson-Jones M, Rafiq S, Siddiqui MK, Teitsson S, Juarez Garcia A, Penrod JR, Using Mixture Cure Models to Improve Survival Extrapolations from Early Follow-Up Data for Nivolumab in NSCLC, Virtual ISPOR Annual European Congress, November 14-18, 2020 15. Milev S, Harris M, Quon P, Vo L, McKenna M, Sun A, Chaudhary MA, Penrod JR, Sorensen S, Considerations and Challenges for Economic Modeling in Non-metastatic Non-small Cell Lung Cancer (nmNSCLC), Virtual ISPOR Annual European Congress, November 14-18, 2020

16. Rafiq S, Chaudhary MA, Siddiqui MK, Vanderpuye-Orgle J, Edmondson-Jones M, Teitsson S, Juarez Garcia A, Penrod JR, Bayesian multi-parameter evidence synthesis to improve long term survival extrapolation with early follow up data from nivolumab NSCLC studies, Virtual ISPOR Annual European Congress, November 14-18, 2020

(Live webinar presentation, Nov 2, 2020)

17. Chaudhary MA, Rafiq S, Siddiqui MK, Vanderpuye-Orgle J, Edmondson-Jones M, Teitsson S, Juarez Garcia, A, Penrod JR, Assessing the performance of landmark response analysis to improve overall survival extrapolation in nivolumab NSCLC trials, Virtual ISPOR Annual European Congress, November 14-18, 2020 (Live webinar presentation, Nov 2, 2020)

18. Chaudhary MA; Sun X; Yuan Y; Varol N; Penrod JR, Estimating EQ-5D Utilities for Cost-effectiveness Models Involving Immuno-oncology Treatments, Virtual ISPOR Annual European Congress, November 14-18, 2020 19. Fu A, Fazeli MS, Kanters S, Siliman G, Chaudhary MA, Gogate A, Kurt M, Investigating Progression-Free Survival as a Potential Surrogate Endpoint for Overall Survival in First-Line Treatment for Glioblastoma Multiforme - A Meta- M. Ashraf Chaudhary, MSc, PhD

September 23

5

Analysis of Randomized Controlled Trials, ISPOR 25th Annual International Meeting (CN4: Live webinar presentation @ virtual conference), May 18, 2020

20. Ward AS, Johnson J, Gupte-Singh K, Chaudhary MA, Dhanda D, Diaz O, Batt K, Fox J, Survival Benefits of Comprehensive Genomic Profiling and Treatment in Metastatic Non-Small Cell Lung Cancer, SITC 34th Annual Meeting, Nov 7-10, 2019 Washington DC, USA

21. Blieden M, Muszbek N, Chaudhary MA, Zhang Y, A Review of Epidemiology, Prognosis, and Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (HNSCC), ISPOR 22nd Annual International Meeting, May 20-24, 2017 Boston MA, USA

22. Farrell J, Jiang Y, Chaudhary MA, Sheppard O, Gathany T, Fan T, A Model of the Cost-effectiveness of Infliximab for the treatment of severely active ulcerative colitis, in Children and Adolescents Aged 6 to 17 Years, Who Have Had an Inadequate Response to Conventional Therapy, ISPOR 16th Annual European Congress, November 2-6, 2013 Dublin, Ireland

23. Chen M, Black CM, Gurunath S, Jansen JP, Chaudhary MA, Fan T, Network Meta-Analysis of Approved Biologic Interventions for the Maintenance of Response in Ulcerative Colitis, ISPOR 16th Annual European Congress, November 2-6, 2013 Dublin, Ireland

24. Chen M, Black CM, Gurunath S, Jansen JP, Chaudhary MA, Fan T, Network Meta-Analysis of Approved Biologic Interventions for the Induction of Response in Ulcerative Colitis, ISPOR 16th Annual European Congress, November 2-6, 2013 Dublin, Ireland

25. Chaudhary MA, Hsu B, Muszbek N, Proskorovsky I, Farrell J. Developing BASDAI and BASFI Predictive Equations from Clinical Trial Data of Golimumab for Severe, Active Ankylosing Spondylitis in Adults. ISPOR 15th Annual European Congress, November 3-7, 2012 Berlin, Germany 26. Farrell J, Muszbek N, Sheppard O, Chaudhary MA, Kachroo S, Naci H. The Long-Term Cost-effectiveness of Golimumab for the Treatment of Severe, Active Ankylosing Spondylitis in Adults Who Have Responded Inadequately to Conventional Therapy. ISPOR 14th Annual European Congress, November 5-8, 2011 Madrid, Spain 27. Chaudhary MA, Elbasha EH, Kumar RN, Lundberg J. PIN33 Cost-Utility Analysis of Raltegravir in HIV-Infected Treatment Naïve Patients in Sweden. Value in Health, 14(3), A119-A119 (2011) 28. Chaudhary MA, Westerhout KY, Fan T, Vos C, Logman JFS, Verheggen BG. PN331: Cost-effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. European Crohn's and Colitis Organization, ECCO ’11 Dublin Congress, Dublin, Ireland, February 24-26, 2011 29. Chaudhary MA, Pereira R, Elbasha EH, Kumar RN, Raltegravir Cost-effectiveness Model for Treatment Naïve HIV Patients in Portugal, PIN34, ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic. 30. Tilden D, Jackson D, LeReun C, Harvey C, Price B, Chaudhary MA, van Bavel J, A Modeled Economic Evaluation of Raltegravir Compared to Standard Practice in Australia for treatment naïve patients with HIV, ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic. 31. Erdesz D, Nagy L, Brandtmuller A, Kiss Z, Chaudhary MA, Kumar, R N, Elbasha EH, An Economic Evaluation of Raltegravir for the Treatment of Antiretroviral-Naive HIV-1 Infected Patients in Hungary, ISPOR 4th Asia-Pacific Conference 5-7 September 2010, Phuket, Thailand.

32. Chaudhary MA, Estimating Incremental Cost-Effectiveness Ratio from Cluster Randomized Studies, 5th International Conference on Statistical Sciences, March 23-25, 2009, Lahore, Pakistan 33. Chaudhary MA, Elbasha EH. Estimating transition matrices to model disease progression in multi-state Markov models, 10th Islamic Countries Conference on Statistical Sciences, December 20-23, 2009 34. Chaudhary MA, Elbasha EH. Raltegravir Cost-Effectiveness Model for Treatment Naïve HIV/AIDS Patients in Canada, Common Drug Review (CDR), Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa Canada, December 1, 2009

35. Elbasha E.H., Szucs T., Chaudhary MA, Kumar R.N., Roediger A., Cook J.R., Opravil M. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV patients in Switzerland. Poster presented at: 17th International AIDS Conference (IAC), August 3-8, 2008, Mexico City, Mexico. 36. Elbasha E.H., Szucs T., Chaudhary MA, Kumar R.N., Roediger A., Cook J.R., Opravil M., Cost-effectiveness analysis of raltegravir in treatment -experienced HIV-1 infected patients in Switzerland. For presentation at: Swiss Society for Infectious Diseases Annual Meeting, August 28-29, 2008, Laussane, Switzerland 37. Chaudhary MA, Moreno, S., Kumar, R.N., Nocea, G., Elbasha E.H. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV patients in Spain. International Aids Economic Network (IAEN) Symposium, August 1-2, 2008 Cuernavaca, Mexico.

38. Elbasha, E., Dunlop, W., Chaudhary MA, and Kumar, RN. An economic evaluation of using raltegravir in treatment- experienced HIV-1 infected patients in the UK. Journal of the International AIDS Society 11 (2008): 1-1 39. Elbasha E.H., Dunlop W., Chaudhary MA, Kumar, R.N. An economic evaluation of using raltegravir in treatment- experienced HIV-1 infected patients in the UK. Drug Therapy in HIV Infection, 9th International Congress, November 9-13, 2008, Glasgow, United Kingdom.

40. Chaudhary MA and M.M. Shoukri: Estimation Incremental Cost-Effectiveness Ratios from Cluster Randomized Intervention Trials, 6th International Conference on Health Policy Research, Boston MA, October 28-30, 2005; 133rd M. Ashraf Chaudhary, MSc, PhD

September 23

6

Annual Meeting of the American Public Health Association, Philadelphia, PA, December 6-10, 2005 (Statistics Section).

Contact this candidate